Abstract
International organizations are calling for One Health approaches to tackle antibiotic resistance (ABR). In France, the diversity of surveillance programmes makes it difficult to get an overview of the current surveillance system and its level of integration. This study aimed to map and characterise all French surveillance programmes for ABR, antibiotic use (ABU) and antibiotic residues in humans, animals, food and the environment, to identify integration points, gaps and overlaps.
A literature review and interviews with 36 programme coordinators were conducted to identify and characterise programmes using a standardized grid (28 variables). Forty-eight programmes were included. They targeted the human (n=35), animal (n=12), food (n=3) and/or the environment (n=1); 35 programmes focused on ABR, 14 on ABU and two on antibiotic residues. Two programmes were cross-sectoral. Among the 35 ABR programmes, 23 collected bacterial isolates. Bacteria most targeted were Escherichia coli (n=17 programmes), Klebsiella pneumoniae (n=13), and Staphylococcus aureus (n=12). ESBL-producing E. coli was monitored by the majority of ABR programmes in humans, animals and food, and is a good candidate for integrated data analysis. ABU indicators were highly variable. Areas poorly covered were the environmental sector, overseas territories, ABR colonisation in humans and ABU in companion animals.
The French surveillance system appears rich and extensive, but with gaps and only few integration points. We believe this mapping will be of high interest to policy makers and surveillance stakeholders, and that our methodology may inspire other countries willing to progress towards One Health surveillance of ABR.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the French Ministry of Agriculture and Food through the EcoAntibio2 programme (research grant 2019-124). The funder contributed to data collection but had no role in data analysis, interpretation or communication of the results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
